BVI has achieved CE marking for Virtuoso®, a pioneering dual-function phaco-vitrectomy platform, designed to enhance surgical control and efficiency in both cataract and vitreoretinal procedures. The first successful patient treatment occurred at LMU Klinikum in Munich in December 2025, marking a significant milestone in the platform’s clinical application. This development follows Virtuoso®’s presentation at major industry forums in 2025 and 2026, where its innovative fluid management and operational efficiency were highlighted.

The significance of Virtuoso® lies in its advanced features, such as the Equality™ fluid control system, which maintains intraocular pressure (IOP) stability throughout surgery, and the Resolute™ ultrasound delivery system, which optimizes energy application based on lens hardness. These innovations promise to improve surgical outcomes by ensuring consistent energy delivery and enhanced aspiration efficiency. Clinical data presented at recent conferences indicate that Virtuoso® can effectively manage post-occlusion pressure surges, demonstrating its potential to transform surgical practices in ophthalmology.

The introduction of Virtuoso® is poised to shift current paradigms in ophthalmic surgical equipment, particularly by offering a flexible, integrated platform that meets the evolving needs of multidisciplinary surgical centers. As BVI prepares for commercial launch in Europe in Q3 2026, the platform not only enhances surgical precision but also supports a streamlined workflow, potentially reducing operating room turnover times. This advancement underscores BVI’s commitment to innovation in ocular health and positions Virtuoso® as a competitive option in the high-end surgical equipment market.

Source: globenewswire.com